Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination
Neuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil<sup>®</sup>, first approved in 2006, i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/7/1132 |
| _version_ | 1797415111194836992 |
|---|---|
| author | Maryam Hatami Moritz Förster Vivien Weyers Saskia Räuber Sven G. Meuth David Kremer |
| author_facet | Maryam Hatami Moritz Förster Vivien Weyers Saskia Räuber Sven G. Meuth David Kremer |
| author_sort | Maryam Hatami |
| collection | DOAJ |
| description | Neuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil<sup>®</sup>, first approved in 2006, is known to be a highly effective prophylaxis against papillomavirus types 6, 11, 16, and 18. Molecularly, this non-infectious recombinant vaccine is based on purified L1 proteins from the human papilloma virus capsid. Since the approval of this vaccine, several studies have investigated its safety regarding the occurrence of autoimmune conditions following application. Here, we present the first case of neuromyotonia with active Gadolinium enhancing demyelinating central nervous system lesions following vaccination with Gardasil<sup>®</sup>. |
| first_indexed | 2024-03-09T05:43:20Z |
| format | Article |
| id | doaj.art-8d2ba642bbdb4f418be2aeed5cd536d3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T05:43:20Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-8d2ba642bbdb4f418be2aeed5cd536d32023-12-03T12:23:25ZengMDPI AGVaccines2076-393X2022-07-01107113210.3390/vaccines10071132Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus VaccinationMaryam Hatami0Moritz Förster1Vivien Weyers2Saskia Räuber3Sven G. Meuth4David Kremer5Department of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyDepartment of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyDepartment of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyDepartment of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyDepartment of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyDepartment of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, GermanyNeuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil<sup>®</sup>, first approved in 2006, is known to be a highly effective prophylaxis against papillomavirus types 6, 11, 16, and 18. Molecularly, this non-infectious recombinant vaccine is based on purified L1 proteins from the human papilloma virus capsid. Since the approval of this vaccine, several studies have investigated its safety regarding the occurrence of autoimmune conditions following application. Here, we present the first case of neuromyotonia with active Gadolinium enhancing demyelinating central nervous system lesions following vaccination with Gardasil<sup>®</sup>.https://www.mdpi.com/2076-393X/10/7/1132neuromyotoniahuman papilloma virusquadrivalent vaccinecentral nervous system lesions |
| spellingShingle | Maryam Hatami Moritz Förster Vivien Weyers Saskia Räuber Sven G. Meuth David Kremer Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination Vaccines neuromyotonia human papilloma virus quadrivalent vaccine central nervous system lesions |
| title | Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination |
| title_full | Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination |
| title_fullStr | Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination |
| title_full_unstemmed | Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination |
| title_short | Neuromyotonia with Central Nervous System Lesions following Quadrivalent Human Papilloma Virus Vaccination |
| title_sort | neuromyotonia with central nervous system lesions following quadrivalent human papilloma virus vaccination |
| topic | neuromyotonia human papilloma virus quadrivalent vaccine central nervous system lesions |
| url | https://www.mdpi.com/2076-393X/10/7/1132 |
| work_keys_str_mv | AT maryamhatami neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination AT moritzforster neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination AT vivienweyers neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination AT saskiarauber neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination AT svengmeuth neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination AT davidkremer neuromyotoniawithcentralnervoussystemlesionsfollowingquadrivalenthumanpapillomavirusvaccination |